Korylan

Paracetamol and Codeine Phosphate Hemihydrate, the active ingredient in Korylan, is an analgesic presented as an oral tablet for oral use. It provides pain relief and reduces fever in patients requiring combined opioid and non‑opioid therapy.

GNH USA supplies Korylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Korylan combines paracetamol and codeine to address pain and fever pathways. It is indicated for: - Mild to moderate pain: Provides analgesic relief when non‑opioid analgesics are insufficient. - Fever: Reduces elevated body temperature. - Post‑operative pain: Assists in managing pain after surgical procedures.

Korylan may cause a range of adverse reactions.

Common Side Effects: - Nausea: Feeling of sickness or upset stomach. - Dizziness: Light‑headed sensation or loss of balance. - Drowsiness: Increased sleepiness or reduced alertness. - Constipation: Difficulty passing stools. - Dry mouth: Reduced salivation. - Vomiting: Expulsion of stomach contents.

Serious or Rare Side Effects: - Respiratory depression: Slowed breathing that can be life‑threatening. - Severe allergic reaction: Rash, swelling, or anaphylaxis. - Hepatotoxicity: Liver injury, especially with overdose. - Dependence or addiction: Risk of misuse with prolonged use. - Hypotension: Unusually low blood pressure. - Seizures: Rare occurrence of convulsive episodes.

When using Korylan, consider the following safety measures: - Assess liver function: Paracetamol may affect hepatic metabolism. - Monitor for opioid dependence: Codeine carries a risk of dependence. - Avoid in severe respiratory disorders: Opioid effect may depress breathing. - Use caution with other CNS depressants: May increase sedation. - Store at ambient temperature: Keep in the original pack, protect from moisture.

Korylan can interact with several medicines; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Other opioids: Additive respiratory depression. - MAO inhibitors: Risk of severe CNS effects. - Alcohol: Enhances sedation and respiratory depression. - CYP2D6 inhibitors: May reduce conversion of codeine to morphine.

Moderate Interactions (Monitor Closely): - Anticoagulants: May increase bleeding risk. - Antihistamines: May heighten drowsiness. - Carbamazepine: May lower paracetamol plasma levels.